Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citi Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)

Tipranks - Tipranks - Thu Mar 12, 5:39AM CDT

Citi analyst Joanne Wuensch maintained a Hold rating on Zimmer Biomet Holdings today and set a price target of $98.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Wuensch is a 4-star analyst with an average return of 3.8% and a 55.83% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Boston Scientific, and Johnson & Johnson.

In addition to Citi, Zimmer Biomet Holdings also received a Hold from Bank of America Securities’s Travis Steed in a report issued on March 2. However, on March 6, Stifel Nicolaus maintained a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH).

See the top stocks recommended by analysts >>

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million

Read More on ZBH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).